About us Newsletter News Widget Media Inquiries

Media Inquiries

Your experience will be better in the app

Install

Sign Up | Log In

Menu

Contact Us Terms of Service Support Privacy Policy Archive

© 2024 Otherweb

Subscribe to our newsletter

Everything you need to know about today's news — in your inbox each morning.

It’s free

By continuing, you agree to Otherweb's Terms of Service and acknowledge you've read our Privacy Policy

Follow

Featured Podcast EpisodesThe Other Web

Alex Fink

Zuckerman vs Zuckerberg

July 14, 2024

Ethan Zuckerman is a professor at the University of Massachusetts Amherst and a scholar of digital media. He and his team work to understand the contemporary digital world and build social media systems that are focused on communities, not on profits. Ethan is currently suing Meta (i.e. Facebook) in a landmark case that might (and likely should) change our interpretation of section 230. Please tune in to hear the details of the case and the various ways it could change the social media landscape. It's fascinating!

Prof. Jeff Jarvis - Rewriting Media's Business Model (Yet Again)

May 24, 2024

Jeff Jarvis is a journalism professor at the City College in New York (CUNY), the author of six books, and the cohost of the successful podcast "This week in Google and AI". Jeff spent many years teaching entrepreneurial journalism - and God knows journalism could use some entrepreneurial spirit, right about now. Please check out Jeff's books, The Gutenberg Parenthesis and Magazine, both from Bloomsbury (discount codes here: gutenbergparenthesis.com).

Donald Robertson - Where Philosophy Meets Psychology

June 22, 2024

Our guest today is Donald Robertson - Donald is a cognitive-behavioral psychotherapist and author of several books, including How to Think Like a Roman Emperor and, more recently, Marcus Aurelius: The Stoic Emperor. He is one of the founders of the Modern Stoicism nonprofit organization and the founder and president of the Plato's Academy Centre in Athens, Greece. He was born in Scotland but now lives in Montreal, Canada. His upcoming book, How to Think Like Socrates, will be released later this year, and can be preordered on Amazon, Barnes and Noble, or anywhere else books are generally sold.

Rick Edmonds - Analyzing the Financial Decline of Legacy Media

July 8, 2024

Rick Edmonds is the media business analyst for the Poynter Institute, a school and study center for working journalists. He has been doing research and writing for 25 years on the financial decline of legacy media, newspapers particularly, and the rise of new media alternatives. His reporting and commentary appear regularly on the Poynter Online site. He has spoken to conference groups in the U.S.A. and in Paris, Norway, Madrid, Vienna and Chile.

Jonathan Green - How To Make ChatGPT and Other Tools Useful (Right Now)

July 5, 2024

Welcome to the Otherweb. Our guest today is Jonathan Green - a bestselling author of hundreds of books, a celebrity ghostwriter, and an expert in using artificial intelligence tools to their utmost capacity. This is the best conversation I've had on the practical implications of ChatGPT and how regular people can augment their own capabilities by using these tools as a shortcut.

1h 4m

News from Novo Nordisk

Stay current with all the latest and breaking news about Novo Nordisk, compare headlines and perspectives between news sources on stories happening today. In total, 35 stories have been published about Novo Nordisk which Ground News has aggregated in the past 3 months.

Recent news

Ars Technica

Ars Technica

Novo Nordisk sells hit weight-loss drug in China—at fraction of US price

Ars Technica

View summary

BBC

BBC

Popular weight-loss drug Wegovy goes on sale in China

BBC

View summary

The Motley Fool

The Motley Fool

Here's why you should buy Viking Therapeutics instead of Eli Lilly

View summary

Latest news stories

Reuters

Reuters

US minority veterans face unequal access to Ozempic and Wegovy, study finds

View summary

Reuters

Reuters

Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S., says CEO

Reuters

View summary

CNBC

CNBC

Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance

CNBC

View summary

Investor's Business Daily

Investor's Business Daily

Madrigal stock soars after Novo Nordisk publishes promising results for weight-loss drug

Investor's Business Daily

View summary

USA Today

USA Today

Diabetes patients worry about insulin shortages as Ozempic use skyrockets

USA Today

View summary

CNBC

CNBC

Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies

CNBC

View summary

Reuters

Reuters

US Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds

Reuters

View summary

Reuters

Reuters

Consumer groups ask FTC to block Novo Holdings-Catalent deal

Reuters

View summary

Reuters

Reuters

US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal

Reuters

View summary

The Motley Fool

The Motley Fool

Prediction: These 2 Stocks Will Join Nvidia, Meta, Apple, Amazon, and Microsoft in the Trillion-Dollar Club by 2030

The Motley Fool

View summary

CNBC

CNBC

Port strike fallout: Blockbuster weight-loss drug supply from Wegovy to Ozempic, Mounjaro, Zepbound, caught up in East Coast trade shutdown

CNBC

View summary

Reuters

Reuters

Evotec and Novo Nordisk in technology development partnership

Reuters

View summary

ABC News

ABC News

Ozempic producer CEO in hot seat in Senate hearing over cost of weight loss drug

ABC News

View summary

CNBC

CNBC

Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices

CNBC

View summary

Fortune

Fortune

Novo Nordisk's market value of $570 billion is more than Denmark's annual GDP

Fortune

View summary

Reuters

Reuters

Novo Nordisk shares drop more than 4% on disappointing obesity pill data

Reuters

View summary

NBC News

NBC News

Bernie Sanders says Ozempic can be produced for less than $100 a month

NBC News

View summary